Combination testing for antibodies in the diagnosis of coeliac disease

Comparison of multiplex immunoassay and ELISA methods

S. Rashtak, M. W. Ettore, H. A. Homburger, Joseph A Murray

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background: Tissue transglutaminase (TTG) antibodies and newly developed deamidated gliadin peptide (DGP) antibodies have better accuracy than native gliadin antibodies. Multiplex immunoassay (MIA) measures multiple antibodies simultaneously providing a complete antibody phenotype with reduced turnaround time and cost. Aim: To evaluate the agreement between MIA and enzyme-linked immunosorbent assay (ELISA) test results for coeliac antibodies in biopsy-proven coeliac patients and controls and to model the diagnostic utility of combination testing. Methods: We compared the sensitivity, specificity and accuracy of MIA and ELISA methods for TTG and DGP antibodies in mainly adult untreated coeliac patients (n = 92) and controls (n = 124). Results: There was excellent agreement and a significant correlation between the results of MIA and ELISA methods (κ > 0.8, r > 0.7) for all tests, except TTG IgG. Diagnostic indices of individual and combination tests measured by the MIA method did not differ significantly from those measured by ELISA. The combination tests slightly increased sensitivity (if any test was positive) and specificity (if all tests were positive) compared to the individual tests. Conclusions: Multiplex immunoassay testing for antibodies is as accurate as ELISA for coeliac disease diagnosis and has practical advantages over ELISA method. Rational combination testing can help identify patients who need intestinal biopsy and may reduce unnecessary biopsies.

Original languageEnglish (US)
Pages (from-to)805-813
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume28
Issue number6
DOIs
StatePublished - Sep 2008

Fingerprint

Celiac Disease
Immunoassay
Enzyme-Linked Immunosorbent Assay
Antibodies
Gliadin
Abdomen
Biopsy
Peptides
Immunoglobulin G
Phenotype
Costs and Cost Analysis
Sensitivity and Specificity
transglutaminase 2

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Combination testing for antibodies in the diagnosis of coeliac disease : Comparison of multiplex immunoassay and ELISA methods. / Rashtak, S.; Ettore, M. W.; Homburger, H. A.; Murray, Joseph A.

In: Alimentary Pharmacology and Therapeutics, Vol. 28, No. 6, 09.2008, p. 805-813.

Research output: Contribution to journalArticle

@article{a22aa99f1025423880dce84412339060,
title = "Combination testing for antibodies in the diagnosis of coeliac disease: Comparison of multiplex immunoassay and ELISA methods",
abstract = "Background: Tissue transglutaminase (TTG) antibodies and newly developed deamidated gliadin peptide (DGP) antibodies have better accuracy than native gliadin antibodies. Multiplex immunoassay (MIA) measures multiple antibodies simultaneously providing a complete antibody phenotype with reduced turnaround time and cost. Aim: To evaluate the agreement between MIA and enzyme-linked immunosorbent assay (ELISA) test results for coeliac antibodies in biopsy-proven coeliac patients and controls and to model the diagnostic utility of combination testing. Methods: We compared the sensitivity, specificity and accuracy of MIA and ELISA methods for TTG and DGP antibodies in mainly adult untreated coeliac patients (n = 92) and controls (n = 124). Results: There was excellent agreement and a significant correlation between the results of MIA and ELISA methods (κ > 0.8, r > 0.7) for all tests, except TTG IgG. Diagnostic indices of individual and combination tests measured by the MIA method did not differ significantly from those measured by ELISA. The combination tests slightly increased sensitivity (if any test was positive) and specificity (if all tests were positive) compared to the individual tests. Conclusions: Multiplex immunoassay testing for antibodies is as accurate as ELISA for coeliac disease diagnosis and has practical advantages over ELISA method. Rational combination testing can help identify patients who need intestinal biopsy and may reduce unnecessary biopsies.",
author = "S. Rashtak and Ettore, {M. W.} and Homburger, {H. A.} and Murray, {Joseph A}",
year = "2008",
month = "9",
doi = "10.1111/j.1365-2036.2008.03797.x",
language = "English (US)",
volume = "28",
pages = "805--813",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Combination testing for antibodies in the diagnosis of coeliac disease

T2 - Comparison of multiplex immunoassay and ELISA methods

AU - Rashtak, S.

AU - Ettore, M. W.

AU - Homburger, H. A.

AU - Murray, Joseph A

PY - 2008/9

Y1 - 2008/9

N2 - Background: Tissue transglutaminase (TTG) antibodies and newly developed deamidated gliadin peptide (DGP) antibodies have better accuracy than native gliadin antibodies. Multiplex immunoassay (MIA) measures multiple antibodies simultaneously providing a complete antibody phenotype with reduced turnaround time and cost. Aim: To evaluate the agreement between MIA and enzyme-linked immunosorbent assay (ELISA) test results for coeliac antibodies in biopsy-proven coeliac patients and controls and to model the diagnostic utility of combination testing. Methods: We compared the sensitivity, specificity and accuracy of MIA and ELISA methods for TTG and DGP antibodies in mainly adult untreated coeliac patients (n = 92) and controls (n = 124). Results: There was excellent agreement and a significant correlation between the results of MIA and ELISA methods (κ > 0.8, r > 0.7) for all tests, except TTG IgG. Diagnostic indices of individual and combination tests measured by the MIA method did not differ significantly from those measured by ELISA. The combination tests slightly increased sensitivity (if any test was positive) and specificity (if all tests were positive) compared to the individual tests. Conclusions: Multiplex immunoassay testing for antibodies is as accurate as ELISA for coeliac disease diagnosis and has practical advantages over ELISA method. Rational combination testing can help identify patients who need intestinal biopsy and may reduce unnecessary biopsies.

AB - Background: Tissue transglutaminase (TTG) antibodies and newly developed deamidated gliadin peptide (DGP) antibodies have better accuracy than native gliadin antibodies. Multiplex immunoassay (MIA) measures multiple antibodies simultaneously providing a complete antibody phenotype with reduced turnaround time and cost. Aim: To evaluate the agreement between MIA and enzyme-linked immunosorbent assay (ELISA) test results for coeliac antibodies in biopsy-proven coeliac patients and controls and to model the diagnostic utility of combination testing. Methods: We compared the sensitivity, specificity and accuracy of MIA and ELISA methods for TTG and DGP antibodies in mainly adult untreated coeliac patients (n = 92) and controls (n = 124). Results: There was excellent agreement and a significant correlation between the results of MIA and ELISA methods (κ > 0.8, r > 0.7) for all tests, except TTG IgG. Diagnostic indices of individual and combination tests measured by the MIA method did not differ significantly from those measured by ELISA. The combination tests slightly increased sensitivity (if any test was positive) and specificity (if all tests were positive) compared to the individual tests. Conclusions: Multiplex immunoassay testing for antibodies is as accurate as ELISA for coeliac disease diagnosis and has practical advantages over ELISA method. Rational combination testing can help identify patients who need intestinal biopsy and may reduce unnecessary biopsies.

UR - http://www.scopus.com/inward/record.url?scp=49849102840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49849102840&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2008.03797.x

DO - 10.1111/j.1365-2036.2008.03797.x

M3 - Article

VL - 28

SP - 805

EP - 813

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 6

ER -